Skip to main content
Top
Published in: BMC Public Health 1/2021

Open Access 01-12-2021 | SARS-CoV-2 | Research article

Age-dependence of healthcare interventions for COVID-19 in Ontario, Canada

Authors: Irena Papst, Michael Li, David Champredon, Benjamin M. Bolker, Jonathan Dushoff, David J. D. Earn

Published in: BMC Public Health | Issue 1/2021

Login to get access

Abstract

Background

Patient age is one of the most salient clinical indicators of risk from COVID-19. Age-specific distributions of known SARS-CoV-2 infections and COVID-19-related deaths are available for many regions. Less attention has been given to the age distributions of serious medical interventions administered to COVID-19 patients, which could reveal sources of potential pressure on the healthcare system should SARS-CoV-2 prevalence increase, and could inform mass vaccination strategies. The aim of this study is to quantify the relationship between COVID-19 patient age and serious outcomes of the disease, beyond fatalities alone.

Methods

We analysed 277,555 known SARS-CoV-2 infection records for Ontario, Canada, from 23 January 2020 to 16 February 2021 and estimated the age distributions of hospitalizations, Intensive Care Unit admissions, intubations, and ventilations. We quantified the probability of hospitalization given known SARS-CoV-2 infection, and of survival given COVID-19-related hospitalization.

Results

The distribution of hospitalizations peaks with a wide plateau covering ages 60–90, whereas deaths are concentrated in ages 80+. The estimated probability of hospitalization given known infection reaches a maximum of 27.8% at age 80 (95% CI 26.0%–29.7%). The probability of survival given hospitalization is nearly 100% for adults younger than 40, but declines substantially after this age; for example, a hospitalized 54-year-old patient has a 91.7% chance of surviving COVID-19 (95% CI 88.3%–94.4%).

Conclusions

Our study demonstrates a significant need for hospitalization in middle-aged individuals and young seniors. This need is not captured by the distribution of deaths, which is heavily concentrated in very old ages. The probability of survival given hospitalization for COVID-19 is lower than is generally perceived for patients over 40. If acute care capacity is exceeded due to an increase in COVID-19 prevalence, the distribution of deaths could expand toward younger ages. These results suggest that vaccine programs should aim to prevent infection not only in old seniors, but also in young seniors and middle-aged individuals, to protect them from serious illness and to limit stress on the healthcare system.
Literature
4.
go back to reference Quach H-L, Hoang N-A. COVID-19 in Vietnam: A lesson of pre-preparation. J Clin Virol. 2020; 127:104379.CrossRef Quach H-L, Hoang N-A. COVID-19 in Vietnam: A lesson of pre-preparation. J Clin Virol. 2020; 127:104379.CrossRef
7.
go back to reference Jefferies S, French N, Gilkison C, Graham G, Hope V, Marshall J, McElnay C, McNeill A, Muellner P, Paine S, et al. COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study. Lancet Public Health. 2020; 5(11):612–23.CrossRef Jefferies S, French N, Gilkison C, Graham G, Hope V, Marshall J, McElnay C, McNeill A, Muellner P, Paine S, et al. COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study. Lancet Public Health. 2020; 5(11):612–23.CrossRef
26.
go back to reference Ontario announces provincewide shutdown to stop spread of COVID-19 and save lives [Press Release]. Ontario Newsroom, Government of Ontario. 2020. https://news.ontario.ca/en/release/59790/ontario-announces-provincewide-shutdown-to-stop-spread-of-covid-19-and-save-lives . Accessed 21 Dec 2020. Ontario announces provincewide shutdown to stop spread of COVID-19 and save lives [Press Release]. Ontario Newsroom, Government of Ontario. 2020. https://​news.​ontario.​ca/​en/​release/​59790/​ontario-announces-provincewide-shutdown-to-stop-spread-of-covid-19-and-save-lives . Accessed 21 Dec 2020.
27.
go back to reference Ontario declares second provincial emergency to address COVID-19 crisis and save lives [Press Release]. Ontario Newsroom, Government of Ontario. 2021. https://news.ontario.ca/en/release/59922/ontario-declares-second-provincial-emergency-to-address-covid-19-crisis-and-save-lives . Accessed 12 Jan 2021. Ontario declares second provincial emergency to address COVID-19 crisis and save lives [Press Release]. Ontario Newsroom, Government of Ontario. 2021. https://​news.​ontario.​ca/​en/​release/​59922/​ontario-declares-second-provincial-emergency-to-address-covid-19-crisis-and-save-lives . Accessed 12 Jan 2021.
30.
go back to reference Riccardo F, Ajelli M, Andrianou X, Bella A, Del Manso M, Fabiani M, Bellino S, Boros S, Urdiales AM, Marziano V, et al. Epidemiological characteristics of COVID-19 cases in Italy and estimates of the reproductive numbers one month into the epidemic. medRxiv. 2020. https://doi.org/10.1101/2020.04.08.20056861. Riccardo F, Ajelli M, Andrianou X, Bella A, Del Manso M, Fabiani M, Bellino S, Boros S, Urdiales AM, Marziano V, et al. Epidemiological characteristics of COVID-19 cases in Italy and estimates of the reproductive numbers one month into the epidemic. medRxiv. 2020. https://​doi.​org/​10.​1101/​2020.​04.​08.​20056861.
31.
go back to reference Davies NG, Klepac P, Liu Y, Prem K, Jit M, Pearson CAB, Quilty BJ, Kucharski AJ, Gibbs H, Clifford S, Gimma A, van Zandvoort K, Munday JD, Diamond C, Edmunds WJ, Houben RMGJ, Hellewell J, Russell TW, Abbott S, Funk S, Bosse NI, Sun YF, Flasche S, Rosello A, Jarvis CI, Eggo RM, CMMID COVID-19 working group. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020; 26(8):1205–11. https://doi.org/10.1038/s41591-020-0962-9.CrossRef Davies NG, Klepac P, Liu Y, Prem K, Jit M, Pearson CAB, Quilty BJ, Kucharski AJ, Gibbs H, Clifford S, Gimma A, van Zandvoort K, Munday JD, Diamond C, Edmunds WJ, Houben RMGJ, Hellewell J, Russell TW, Abbott S, Funk S, Bosse NI, Sun YF, Flasche S, Rosello A, Jarvis CI, Eggo RM, CMMID COVID-19 working group. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020; 26(8):1205–11. https://​doi.​org/​10.​1038/​s41591-020-0962-9.CrossRef
37.
go back to reference Zhao M, Wang M, Zhang J, Gu J, Zhang P, Xu Y, Ye J, Wang Z, Ye D, Pan W, Shen B, He H, Liu M, Liu M, Luo Z, Li D, Liu J, Wan J. Comparison of clinical characteristics and outcomes of patients with Coronavirus Disease 2019 at different ages. Aging. 2020; 12:10070–86. https://doi.org/10.18632/aging.103298.CrossRef Zhao M, Wang M, Zhang J, Gu J, Zhang P, Xu Y, Ye J, Wang Z, Ye D, Pan W, Shen B, He H, Liu M, Liu M, Luo Z, Li D, Liu J, Wan J. Comparison of clinical characteristics and outcomes of patients with Coronavirus Disease 2019 at different ages. Aging. 2020; 12:10070–86. https://​doi.​org/​10.​18632/​aging.​103298.CrossRef
40.
go back to reference R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2019. https://www.R-project.org/. R Foundation for Statistical Computing. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2019. https://​www.​R-project.​org/​. R Foundation for Statistical Computing.
41.
go back to reference Wood SN. Generalized additive models: An introduction with R, 2nd ed. Boca Raton, Florida, USA: Chapman and Hall/CRC; 2017.CrossRef Wood SN. Generalized additive models: An introduction with R, 2nd ed. Boca Raton, Florida, USA: Chapman and Hall/CRC; 2017.CrossRef
46.
go back to reference Gorna R, MacDermott N, Rayner C, O’Hara M, Evans S, Agyen L, Nutland W, Rogers N, Hastie C. Long COVID guidelines need to reflect lived experience. Lancet. 2021; 397(10273):455–7.CrossRef Gorna R, MacDermott N, Rayner C, O’Hara M, Evans S, Agyen L, Nutland W, Rogers N, Hastie C. Long COVID guidelines need to reflect lived experience. Lancet. 2021; 397(10273):455–7.CrossRef
50.
go back to reference Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T. Efficacy and safety of the MRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021; 384(5):403–16. https://doi.org/10.1056/NEJMoa2035389. PMID: 33378609.CrossRef Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T. Efficacy and safety of the MRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021; 384(5):403–16. https://​doi.​org/​10.​1056/​NEJMoa2035389. PMID: 33378609.CrossRef
51.
go back to reference Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397(10275):671–681. https://doi.org/10.1016/S0140-6736(21)00234-8.CrossRef Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397(10275):671–681. https://​doi.​org/​10.​1016/​S0140-6736(21)00234-8.CrossRef
52.
go back to reference Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021. https://doi.org/10.1016/S0140-6736(21)00432-3. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021. https://​doi.​org/​10.​1016/​S0140-6736(21)00432-3.
Metadata
Title
Age-dependence of healthcare interventions for COVID-19 in Ontario, Canada
Authors
Irena Papst
Michael Li
David Champredon
Benjamin M. Bolker
Jonathan Dushoff
David J. D. Earn
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2021
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-021-10611-4

Other articles of this Issue 1/2021

BMC Public Health 1/2021 Go to the issue